ADC Therapeutics reports Q4'23 ZYNLONTA sales $16.6M, net loss $85M; cash runway into Q4'25

ADC Therapeutics SA

ZYNLONTA net sales $16.6M in Q4'23 (+17% QoQ, -16% YoY); FY'23 $69.1M (-8% YoY).
Net loss $85M in Q4'23 ($1.03/share) vs $23.3M loss in Q4'22; FY'23 net loss $240.1M ($2.94/share).
Cash $278.6M, expected runway into Q4'25; operating expenses decreased 21% YoY.
LOTIS-5 may need additional patients beyond 350; enrollment still expected to complete in 2024.
ADCT-601 pancreatic cancer screening initiated; LOTIS-7 dose escalation cleared at 150 µg/kg.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADC Therapeutics SA reported financial results for fourth quarter and full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 13, 2024, ADC Therapeutics SA (the “Company”) issued a press release and made available a corporate presentation announcing the Company’s financial results for the full year and fourth quarter ended December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ADC Therapeutics SA filing history →

Source: SEC EDGAR

accession 0001628280-24-010785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.